```html

Keratitis Sicca (Dry Eye Syndrome) – Comprehensive Medical Guide

Overview

Keratitis sicca, more commonly called dry eye syndrome, is a multifactorial disease of the ocular surface characterized by insufficient tear production, excessive tear evaporation, or both. The resulting tear film instability leads to inflammation and damage to the cornea and conjunctiva.

Dry eye can affect anyone, but it is most prevalent among:

• Adults over 50 years old
• Women (especially post‑menopausal)
• Contact‑lens wearers
• Individuals with chronic autoimmune diseases (e.g., Sjögren’s syndrome, rheumatoid arthritis)

According to the American Academy of Ophthalmology, up to 16 million Americans (≈ 7% of the U.S. population) experience clinically significant dry eye, and prevalence rises to >30% in people older than 65.

Symptoms

Symptoms can range from mild irritation to severe pain and visual disturbance. They often fluctuate throughout the day and may be aggravated by environmental factors.

• Burning or stinging sensation – a feeling of heat on the ocular surface.
• Foreign‑body sensation – the impression that something is stuck in the eye.
• Redness (conjunctival hyperemia) – due to inflammation of tiny blood vessels.
• Excessive tearing (reflex tearing) – paradoxically, the eye may water as a protective response.
• Blurred vision – especially after reading, computer work, or exposure to wind.
• Photophobia – increased sensitivity to light.
• Eye fatigue – difficulty keeping the eyes open for long periods.
• Mucous or stringy discharge – a sign of poor tear quality.
• Difficulty wearing contact lenses – lenses become uncomfortable or have reduced wear time.
• Fluctuating visual acuity – vision may clear when blinking and become hazy afterward.

Symptoms often worsen in low‑humidity environments, while using heating/air‑conditioning, or after prolonged screen time.

Causes and Risk Factors

Primary mechanisms

1. Aqueous‑deficient dry eye – reduced tear production by the lacrimal glands (e.g., Sjögren’s syndrome, age‑related decline).
2. Evaporative dry eye – excessive tear evaporation due to meibomian gland dysfunction (MGD), eyelid abnormalities, or a hostile environment.
3. Mixed type – most patients have components of both mechanisms.

Common risk factors

• Age > 50 years
• Female sex (estrogen deficiency after menopause)
• Autoimmune disorders (Sjögren’s, rheumatoid arthritis, lupus)
• Medications that reduce tear production (antihistamines, decongestants, antidepressants, isotretinoin, beta‑blockers)
• Digital device use (>2 hours/day) – reduced blink rate
• Environmental exposure (dry wind, air‑conditioned or heated rooms, smoke)
• Contact lens wear (especially soft lenses)
• Ocular surgeries (LASIK, cataract extraction) that disrupt corneal nerves
• Systemic conditions: diabetes, thyroid disease, vitamin A deficiency

Diagnosis

The diagnosis is clinical but supported by several objective tests.

History and symptom questionnaires

• OSDI (Ocular Surface Disease Index) – a validated 12‑item questionnaire; scores ≥23 suggest moderate to severe dry eye.
• DEQ‑5 (Dry Eye Questionnaire‑5) – quick screen used in primary care.

Clinical examination

1. Slit‑lamp biomicroscopy – evaluates tear meniscus, conjunctival redness, lid margin, and corneal staining.
2. Fluorescein staining – highlights epithelial defects; graded using the Oxford or NEI scale.
3. Lissamine green or Rose Bengal staining – assesses devitalized cells on the conjunctiva.
4. Schirmer test – filter paper placed under the lower eyelid for 5 minutes; ≤5 mm wetting indicates aqueous deficiency.
5. Tear Break‑Up Time (TBUT) – fluorescein dye is applied; time ≤10 seconds suggests tear film instability.
6. Meibography – infrared imaging of meibomian glands to detect dropout or obstruction.

Additional investigations (when indicated)

• Serologic testing for Sjögren’s (anti‑SSA/Ro, anti‑SSB/La antibodies).
• Ocular surface temperature mapping.
• Tear osmolarity measurement (≥308 mOsm/L is diagnostic).

Treatment Options

Treatment follows a stepwise approach, from simple lubricants to advanced therapies, tailored to severity and underlying cause.

1. Lifestyle and environmental modifications

• Increase ambient humidity (humidifier, especially at night).
• Take regular 20‑second breaks every 20 minutes of screen work (the “20‑20‑20 rule”).
• Avoid direct airflow from fans, hairdryers, or air‑conditioning vents.
• Wear sunglasses outdoors to reduce wind exposure.
• Stay hydrated; aim for 2–3 L of water daily.

2. Over‑the‑counter (OTC) lubricants

• Artificial tears (preservative‑free for severe cases) – sodium hyaluronate, carboxymethylcellulose, or polyethylene glycol formulations.
• Ointments/gels – for nighttime use; provide longer residence time.
• Frequency: 4–6 times daily for mild disease; up to every 1–2 hours for severe disease.

3. Prescription medications

1. Ciclosporin A ophthalmic emulsion (0.05%) – anti‑inflammatory, improves tear production; onset 4–6 weeks.
2. Lifitegrast 5% eye drops – blocks LFA‑1/ICAM‑1 interaction, reducing ocular surface inflammation.
3. Topical corticosteroids (short‑term) – for acute flares; must be tapered to avoid glaucoma or cataract.
4. Oral tetracyclines (doxycycline 40 mg daily) – anti‑proteinase activity improves meibomian gland function.
5. Autologous serum eye drops – contain growth factors; reserved for refractory, severe cases.

4. Procedural and device‑based therapies

• Punctal plugs (silicone or collagen) – block tear drainage, retaining tears on the ocular surface.
• Thermal pulsation (e.g., LipiFlow) – applies heat and pressure to clear meibomian gland obstruction.
• Meibomian gland expression – performed in‑office with specialized instruments.
• Intense pulsed light (IPL) – reduces ocular surface inflammation and improves gland function.
• Low‑level light therapy (LLLT) and neuro‑stimulation devices – emerging options that stimulate tear production.

5. Surgical options (rare)

In extremely refractory cases, conjunctival transplantation** or **tarsorrhaphy** may be considered, but these are uncommon and reserved for severe ocular surface disease.

Living with Keratitis sicca (dry eye syndrome)

Daily management checklist

1. Morning routine: Apply preservative‑free artificial tears before makeup; use warm compress for 5 minutes to melt meibum.
2. Work environment: Keep a humidifier at desk; position monitor at eye level to reduce upward gaze.
3. Mid‑day break: Blink consciously; perform a brief lid massage (upward‑then‑downward motion) to express glands.
4. Evening: Re‑apply lubricants; use a nighttime ointment if dryness intensifies at night.
5. Contact lens wearers: Switch to daily disposables or glasses when symptoms flare; ensure proper lens hygiene.
6. Nutrition: Eat omega‑3 rich foods (salmon, walnuts) or consider 1 g EPA/DHA supplement daily (shown to improve tear stability).
7. Follow‑up: Keep regular appointments with an eye care professional—typically every 6–12 months or sooner if symptoms change.

Psychosocial considerations

Dry eye can affect quality of life, work productivity, and mood. Encourage patients to discuss any frustration or anxiety with their eye care provider, who may refer to counseling or support groups.

Prevention

• Limit exposure to smoke, wind, and low‑humidity environments.
• Take regular breaks during prolonged screen time (20‑20‑20 rule).
• Maintain a balanced diet rich in omega‑3 fatty acids and vitamin A.
• Stay hydrated; avoid excessive caffeine or alcohol, which can dehydrate the body.
• Review medications with a physician—some drugs can be switched to alternatives with less ocular dryness.
• Practice proper eyelid hygiene: warm compresses and gentle lid scrubs (e.g., diluted baby shampoo) 1–2 times weekly.
• Use protective eyewear when swimming or in dusty environments.

Complications

If left untreated, chronic keratitis sicca can lead to:

• Corneal epithelial erosions or persistent epithelial defects.
• Scarring of the cornea (neovascularization) that may impair vision.
• Increased risk of bacterial, fungal, or viral keratitis.
• Development of conjunctival punctate keratopathy.
• Reduced contact lens tolerance and eventual intolerance.
• Reduced quality of life, including difficulty reading, driving at night, or performing work tasks.

When to Seek Emergency Care

Call 911 or go to the nearest emergency department if you experience any of the following:

• Sudden, severe eye pain that does not improve with blinking.
• Rapid loss of vision or a large “black spot” in the visual field.
• Sudden onset of heavy eye redness combined with discharge (possible infectious keratitis).
• Significant trauma to the eye (chemical splash, foreign body penetration).
• Corneal ulcer suspected (persistent ulcer on fluorescein staining, worsening despite treatment).

These signs may indicate an acute infection, corneal ulcer, or other sight‑threatening condition that requires immediate ophthalmologic evaluation.

---

Sources: Mayo Clinic, American Academy of Ophthalmology, National Eye Institute (NEI), CDC, WHO, Cleveland Clinic, Ophthalmology journal (2022), Eye journal (2023).

```